Drug Type Bispecific antibody |
Synonyms- |
Target |
Action agonists |
Mechanism NRP-2 agonists(Neuropilin 2 agonists), PLXNA1 agonists(plexin A1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 01 Feb 2026 | |
| Neoplasms | Preclinical | - | 01 Feb 2026 | |
| Neoplasms | Preclinical | - | 01 Feb 2026 |






